Start and Grow a Profitable Botox®, Aesthetic Medicine or Medical Weight Management Practice

Home » Medical Weight Management Library  » Comparing Saxenda® and Victoza®

Comparing Saxenda® and Victoza®

Saxenda® and Victoza® are two medications manufactured by Novo Nordisk, garnering significant attention for their roles in weight management and diabetes control. These pharmaceutical products offer distinct features and serve specific purposes, making it essential to compare their attributes for those seeking improved health outcomes. In this comparison, we will delve into the unique characteristics, applications, mechanisms of action, and potential benefits of Saxenda® and Victoza®.
Comparing Saxenda® and Victoza®

Table of Contents

What are the main differences between Saxenda® and Victoza®?

Saxenda® and Victoza® are both brand-name drugs manufactured by Novo Nordisk. They are both injectable medications that share the same active ingredient, liraglutide. Despite these similarities, they are approved by the FDA for different uses. Saxenda® is approved as a weight loss treatment for obese or overweight adults, while Victoza® is designed for the management of type-2 diabetes. Although they share the same active ingredient, the dosages of the drugs differ. Saxenda® contains a higher dose of liraglutide, which contributes to its weight-loss effects. The primary role of Victoza® involves the maintenance of blood sugar levels, helping to improve the body’s response to insulin and reducing levels of glucose produced by the liver. On the other hand, Saxenda® works by mimicking a hormone found in the intestines, manipulating the brain to feel satiated, thus helping to control appetite and calorie intake. While both Saxenda® and Victoza® can induce weight loss, it’s essential to note that the former is specifically designed for this purpose, while the latter’s weight-loss effects are more of a beneficial side effect. Victoza® is usually prescribed as part of a broader treatment plan for diabetes, which may include diet and exercise, and possibly other diabetic medications. Saxenda® is also typically part of a comprehensive weight-loss plan, encompassing dietary changes and physical activity. The administration method also differs; Saxenda® is intended specifically for subcutaneous use, while Victoza® can also be utilized intra-muscularly. The needles used for their administration may differ as a result. Finally, while there are similarities in possible side effects, such as nausea, vomiting, or diarrhea, certain side effects are more unique to each medication. Saxenda®, for instance, might cause hypoglycemia in patients with type 2 diabetes on medicines that increase insulin production. Despite having the same active ingredient, Saxenda® and Victoza® serve distinctive healthcare needs depending on an individual’s specific condition, either aiding in weight loss or managing type-2 diabetes.

How are Saxenda® and Victoza® used in weight management?

Saxenda® and Victoza®, though having different primary indications, can both play a role in weight management. Saxenda® is specifically approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related condition like hypertension, type 2 diabetes, or high cholesterol. Saxenda® works by mimicking a hormone that targets areas of the brain that regulate appetite and eating behavior, leading to reduced hunger and increased feelings of fullness. It is not a replacement for a healthy diet or regular exercise, but instead is part of an overall weight management plan that includes these lifestyle changes. Victoza®, while primarily used for the treatment of type-2 diabetes, has also been observed to result in weight loss. Studies have shown that liraglutide, the active ingredient in both Saxenda® and Victoza®, aids in weight loss by slowing gastric emptying and increasing feelings of fullness. However, the weight-loss effect of Victoza® is often considered an ancillary benefit to its primary purpose of regulating blood sugar levels in people with type-2 diabetes. The weight loss experienced with Victoza® is typically not as pronounced as that with Saxenda® due to the lower dosage of liraglutide in Victoza®. Both Saxenda® and Victoza® are administered daily via subcutaneous injection. The recommended dose of Saxenda® for weight management is 3 mg daily while Victoza® is started at 0.6 mg per day for diabetes, increased to a maximum of 1.8 mg per day, depending on the patient’s glycemic response and tolerance. The duration of treatment with Saxenda® or Victoza® for weight loss is not set in stone. It often depends on the individual’s response to treatment and whether the benefits of weight loss, such as improved blood sugar control or lower blood pressure, outweigh the potential risks and side effects. Early clinical trials and observational studies have shown that both drugs contribute to significant weight loss, especially when combined with lifestyle modifications. However, as with all medications, results can vary significantly from person to person. In summary, both Saxenda® and Victoza® contain the same active ingredient and can result in weight loss, although the degree and purpose of this effect differ. It’s crucial for individuals to discuss these options with their healthcare provider to determine which treatment aligns best with their health goals and medical conditions.

Learn to Start a Profitable Aesthetics Practice in Just 4-Days!

May 31-June 3 (only 4 spots left!)
September 6-9
October 18-21

in sunny Scottsdale, AZ

Learn the clinical and business skills you need to transform your work/life balance with a profitable aesthetics practice in just

Dates: May 31-June 3 (only 4 spots left!), September 6-9 and October 18-21

Scottsdale, AZ

Only $4,195*

Earn 33.5 CMEs

*Members preferred price for 4-day accelerated program. Membership is only $295/yr and can be added during registration.

What side effects can you expect from Saxenda® and Victoza®?

Saxenda® and Victoza®, being the brand names for liraglutide, share some similar side effects, each stemming from their common active ingredient. However, due to the different doses and applications, some side effects may be more pronounced with one over the other. Both Saxenda® and Victoza® can cause mild to moderate gastrointestinal symptoms initially. These symptoms include nausea, vomiting, diarrhea, and constipation. For many people, these symptoms decrease over time as the body adjusts to the medication. Saxenda®, prescribed specifically for weight loss, can cause hypoglycemia in people with type 2 diabetes who also take medications to treat their condition. Hypoglycemia, or low blood sugar, is identified by symptoms such as shaking, sweating, fast heartrate, and blurred vision. Other common side effects of Saxenda® are related to its mechanism of action in the body. These include a loss of appetite, indigestion, and a feeling of fatigue. In rare cases, Saxenda® may cause serious side effects, like pancreatitis, gallbladder disease, or kidney damage. Victoza®, while also causing gastrointestinal upset, is more associated with a potential risk of thyroid cancer. Animal studies have shown a link between liraglutide and thyroid cancer, and as a result, Victoza® carries a boxed warning about this potential risk. Potential side effects also include inflamed pancreas, severe abdominal pain, and kidney issues, often denoted by decreased urination, swelling in lower limbs/ankles, or feeling tired. Both medications can cause allergic reactions, with symptoms such as hives, rash, difficulty breathing, and swelling of face, lips, tongue, or throat. Any of these accelerated symptoms should be reported to a healthcare provider immediately. The risk of side effects can increase when used simultaneously with other medications or substances such as alcohol. Therefore, discussing your complete medical history and current medication list with your doctor is crucial before starting any new medication. Overall, understanding potential side effects plays a crucial role in making an informed decision about medication choice. Both Saxenda® and Victoza® have their distinct side effects profile, which should be thoroughly discussed with healthcare providers.

How does the cost of Saxenda® compare to Victoza®?

Cost is a critical factor for many patients when considering medication options. When comparing Saxenda® and Victoza®, there are significant differences despite them containing the same active ingredient, liraglutide. As a weight loss treatment, Saxenda® is not universally covered by all health insurance plans, and even when it is, co-pays can be high. The cost of Saxenda® can vary widely depending on individual insurance coverage. Without insurance, Saxenda® can cost around $1300 to $1400 for a 30-day supply. Victoza® is primarily used to treat Type-2 diabetes, which is more likely to be covered under many health insurance plans. Still, coverage can vary widely by provider and plan. Uninsured or underinsured patients may face out-of-pocket costs of about $800 to $900 for a 30-day supply. Both Saxenda® and Victoza® offer assistance programs to help eligible patients afford the medications. They may include savings cards for eligible patients with private insurance and patient assistance programs for those without insurance. Several generic alternatives to Saxenda® and Victoza® have been approved by the FDA, which could help patients save on medication costs. However, these alternatives may not be as effective or have the same side-effect profiles as the branded versions. Purchasing larger quantities or using mail-order pharmacies can sometimes help lower per-dose costs. However, patients should ensure that these sources are licensed and regulated to ensure that they are receiving a safe and effective product. It’s important to note that the cost should not be the sole deciding factor when choosing between Saxenda® and Victoza®. Efficacy, side-effect profile, and individual health goals should also be considered. Discussing medication costs with healthcare providers can help patients make informed decisions about their treatment. Providers may have suggestions for cost-saving strategies or alternative treatments if cost is a significant concern. In summary, Victoza® is typically less expensive than Saxenda®, but individual costs may vary based on several factors, including individual health insurance coverage, assistance programs, and personal medication needs.

The Fastest Way to Increase Your Knowledge of Aesthetic Medicine

On-Demand Training with the IAPAM Learning Lab

Sign up today and expand your knowledge & skills in Botox®, Fillers, Lasers,
Chemical Peels, Microdermabrasion and PRP for Aesthetics!

How effective are Saxenda® and Victoza® in the management of type-2 diabetes?

Managing type-2 diabetes involves balancing blood glucose levels, and both Saxenda® and Victoza® can play a role in that strategy, albeit in different ways. Victoza® is specifically designed and approved for type-2 diabetes management, while Saxenda® is primarily a weight loss drug that may indirectly impact blood glucose control. Victoza® is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that improve blood sugar control by mimicking the actions of the body’s incretin hormones. These actions include stimulating insulin secretion, slowing gastric emptying, and suppressing inappropriate post-meal glucagon release, each contributing to lower blood glucose levels. Saxenda®, while designed for weight loss using a higher dosage of liraglutide, can influence blood glucose indirectly. The weight loss caused by Saxenda® can lead to overall improved metabolism, including better blood sugar control. However, Saxenda® isn’t typically prescribed as a first-line treatment for type-2 diabetes due to its primary role as a weight-loss drug and its cost. It may be considered if the patient with type-2 diabetes has a significant need for weight loss and hasn’t responded well to other treatments. Comparative clinical trials have found Victoza® to effectively lower HbA1c, a long-term measure of blood glucose control, and improve fasting plasma glucose levels. Its benefit on cardiovascular outcomes has also been seen in patients with type-2 diabetes at high cardiovascular risk. Both drugs do come with potential side effects, including hypoglycemia. However, the risk of severe hypoglycemia with either drug is relatively low unless combined with a sulfonylurea or insulin, which are more likely to cause hypoglycemia. It’s crucial to keep in mind that both Saxenda® and Victoza® are parts of comprehensive type-2 diabetes and weight management plans, and work best when combined with healthy lifestyle changes like a balanced diet and regular physical activity. In conclusion, while Saxenda® and Victoza® both have roles in managing type-2 diabetes, they’re used differently based on individual patient needs. Their use should be guided by healthcare professionals adept in understanding their unique benefits and potential risks.

Are there any serious health risks associated with Saxenda® and Victoza®?

While Saxenda® and Victoza® are both beneficial for weight management and blood glucose control respectively, they come with potential serious health risks that users must be aware of. Saxenda® carries a boxed warning for a potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This risk was identified in animal trials, and it’s unclear whether Saxenda® raises this risk in humans. However, Saxenda® is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Apart from the risk of MTC, Saxenda® can also increase the risk of severe pancreatitis. Symptoms like severe abdominal pain that may reach your back and may accompany vomiting should be taken seriously. Victoza® shares similar risks to Saxenda® regarding possible thyroid tumors. The medication guide for Victoza® carries a warning about unusual lumps or swelling in the neck, trouble swallowing, or a hoarse voice as signs of possible thyroid tumors. Another serious health risk associated with Victoza® is pancreatitis. It’s advised to stop using Victoza® and seek medical help if you have severe stomach pain that will not disappear and is sometimes felt at the back. Both medications may cause changes in urination, which can be a sign of kidney problems. Users with kidney problems taking either Saxenda® or Victoza® should have their kidney function monitored closely by a healthcare provider. More rarely, Saxenda® and Victoza® may cause an allergic reaction, including anaphylaxis or angioedema, which can be life-threatening and require immediate medical attention. It’s worth noting that the FDA continues to monitor the safety of both Saxenda® and Victoza® after they’re on the market to identify any previously unrecognized safety concerns. Any detected issues are then communicated to the public. Healthcare providers play a crucial role in guiding patients on these medications and managing potential risks. Patients should always discuss thoroughly with healthcare professionals before starting either of these medications. In conclusion, while both Saxenda® and Victoza® provide health benefits, they both carry significant health risks that need to be understood and monitored closely.

Can you use Saxenda® and Victoza® simultaneously for better results?

Saxenda® and Victoza® both utilize liraglutide as their active ingredient, though for different purposes: Saxenda® focuses on weight management, while Victoza® is intended for managing type-2 diabetes. As such, a common question arises as to whether the two can be used concurrently for better results. Generally, the recommendation is against the simultaneous usage of Saxenda® and Victoza®. This is primarily due to both medications containing the same active ingredient, which means using them in combination could lead to an overdose of liraglutide. The dose of liraglutide in Saxenda® is significantly higher than in Victoza®, to promote weight loss in patients who are overweight or obese. Using them together would exceed the recommended dose of the medication, potentially leading to severe side effects. Such side effects could include severe nausea, vomiting, and diarrhea, which are common side effects of both Saxenda® and Victoza® but may be amplified with usage together. There may also be an increased risk of more severe side effects, like pancreatitis or kidney problems. In some cases, patients may wish to switch from Victoza® to Saxenda® for added weight loss benefits. This switch should only be made under the guidance of a healthcare professional to avoid potential adverse effects. It’s also vital to note that both Saxenda® and Victoza® require injection, and simultaneous use could lead to issues at the injection site or a general reluctance towards the regimen due to the higher number of injections. In conclusion, due to the shared active ingredient and potential for increased side effects, it is advised against using Saxenda® and Victoza® simultaneously. As always, consultation with a healthcare provider is critical when altering medication regimens.

What are the clinical trial results for Saxenda® vs Victoza®?

As prescription drugs, both Saxenda® and Victoza® have undergone rigorous clinical trials to assess their efficacy, safety, and side-effect profiles. Understanding the results of these trials is critical for making informed decisions about treatment options. Saxenda® was examined in clinical studies that involved approximately 4500 overweight and obese patients with and without weight-related conditions. Across trials, patients taking Saxenda® experienced significantly greater weight loss over 56 weeks compared to patients taking a placebo. In one trial involving patients without weight-related comorbidities, Saxenda® led to an average weight loss of 4.5% compared to placebo. In another trial with patients with weight-related comorbidities, Saxenda® resulted in an average weight loss of 5.9% compared to placebo. Victoza®, on the other hand, has been tested in numerous studies for its efficacy in managing type-2 diabetes. Across clinical trials, Victoza® demonstrated significant reductions in HbA1c, fasting plasma glucose, and body weight compared to placebo and other active comparator drugs. In a 26-week, randomized, open-label trial comparing Victoza® to a popular oral anti-diabetic drug, Victoza® resulted in an average HbA1c decrease of 1.1% compared to 0.4% with the comparator drug. Victoza® also consistently reduced body weight in clinical trials, although weight loss is not its primary purpose. Both Saxenda® and Victoza® were generally well-tolerated in clinical trials. Much of the adverse events reported were mild to moderate in severity, and often lessened over time. Frequently reported adverse events included gastrointestinal symptoms, such as nausea and diarrhea. It is important to remember that while clinical trial results provide valuable insights into medication performance, individual experiences may differ. Various factors like genetic make-up, lifestyle choices and existing medical conditions can influence how a person responds to medication. Conclusively, both Saxenda® and Victoza® have demonstrated efficacy in their respective core applications through systematic clinical trials. These trials form the bedrock of their FDA approval and guide their usage recommendations.

How does the method of administration differ between Saxenda® and Victoza®?

Both Saxenda® and Victoza® are administered using subcutaneous injections, but there are slight differences due to their different intent of use and dosage. Saxenda® is intended for use as a long-term weight management therapy for obese or overweight adults. The recommended dosage is 3.0 mg daily, injected subcutaneously (under the skin) in the abdomen, thigh, or upper arm. The initial dose of Saxenda® should be 0.6 mg per day for the first week, with the dose gradually increased over several weeks to reduce gastrointestinal side effects. Victoza®, primarily used to manage blood sugar levels in adults with type-2 diabetes, is also injected subcutaneously in the abdomen, thigh, or upper arm. The initial dosage for Victoza® is 0.6 mg per day. Depending on how well the patient tolerates it and their response to the medication, the dose can be increased to 1.2 mg or 1.8 mg per day. Both Saxenda® and Victoza® come in pre-filled, multi-dose pens that can deliver doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg. Each pen contains 18 mg of liraglutide and can deliver doses of up to 3.0 mg for 6 days. Regarding timing, Saxenda® can be administered at any time of day, without regard to meals, while Victoza® should ideally be administered at the same time each day. It’s important to note that proper education and training on how to use the Saxenda® and Victoza® injection pens are crucial to ensure correct administration and to minimize potential side effects. In conclusion, both Saxenda® and Victoza® are administered as subcutaneous injections, but the dosage and timing may differ. It’s essential for individuals to follow their healthcare professional’s advice on the dosage and administration method for these medications.

What are patient experiences like with Saxenda® and Victoza®?

Patient experiences can provide insightful real-world data on medication usage, effectiveness, and side effects. This includes both Saxenda® and Victoza®, each having a large body of anecdotal evidence from users. Feedback from patients using Saxenda® for weight loss is varied. Many have reported significant weight loss within the first few months, while others mention a more gradual decrease. It’s common for patients to report decreased appetite and feeling full more quickly, reinforcing Saxenda®’s intended mechanism of action. Side effects with Saxenda®, like nausea, diarrhea, and constipation, are commonly reported but they seem to decrease over a few weeks for most users. Rarely, some patients have reported more severe side effects like pancreatitis, which requires immediate medical attention. On the topic of Victoza®, patients have reported a positive impact on their blood sugar control, often experiencing lower fasting glucose levels and a reduction in HbA1c. An appreciable number of patients also reported weight loss as a fringe benefit. Similar to Saxenda®, users of Victoza® commonly experienced gastrointestinal side effects, but these were typically transient, disappearing after continued use. More serious side effects like pancreatitis and allergic reactions, though rare, were also reported by some users. Many users of both Saxenda® and Victoza® commented on the ease of use of the multi-dose pen, expressing that it made the daily injections more comfortable and straightforward. But to balance these experiences, it’s crucial to remember that individual experiences vary widely and may not be fully representative of what every patient may encounter. Climate, lifestyle habits, adherence to therapy, concomitant medications all contribute to the individual response to any medication, including Saxenda® and Victoza®. In conclusion, while the patient experiences offer valuable firsthand insights into the usage and side effects of Saxenda® and Victoza®, it’s important to consider these alongside medical advice and scientific evidence.
The Most Comprehensive Botox® Training Program
Learn everything you need to transform your life to making more and working less by growing your own profitable aesthetics practice or medical spa!
May 31-June 3 (only 3 spots left!)

Scottsdale, Arizona